Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record.

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

Bendell, Johanna C., Kim, Tae Won, Goh, Boon C., Wallin, Jeffrey, Oh, Do-Youn, Han, Sae-Won, Lee, Carrie B., Hellmann, Matthew David, Desai, Jayesh, Lewin, Jeremy Howard, Solomon, Benjamin J., Chow, Laura Quan Man, Miller, Wilson H., Gainor, Justin F., Flaherty, Keith, Infante, Jeffrey R., Das-Thakur, Meghna, Foster, Paul, Cha, Edward, Bang, Yung-Jue·2016·Journal of Clinical Oncology

Abstract

3502 Background: Atezolizumab (atezo; MPDL3280A) is an engineered antibody that inhibits binding of PD-L1 to its receptors, PD-1 and B7.1. Atezo has demonstrated monotherapy activity in a multitude of human tumor types. However, response rates in microsatellite stable (MSS) CRCs have been lower than in other indications. In preclinical models, targeted inhibition of MEK leads to upregulation of MHC I on tumor cells, induces intratumoral T-cell infiltration and enhances anti-PDL1 activity. We therefore conducted a Phase Ib study combining cobi (MEK inhibitor) and atezo in patients (pts) with advanced solid tumors. Methods: Cobi was escalated from 20 to 60 mg daily (21 days on/7 days off) and combined with atezo 800 mg IV q2w. Tumor-specific expansion cohorts, including KRAS-mutant CRC, and serial biopsy cohorts in solid tumors were opened upon determination of the MTD. Safety, tolerability and confirmed ORR by RECIST v1.1 were evaluated. Results: As of October 12, 2015, 23 CRC (22 KRAS mutant, 1 WT) pts were enrolled during escalation and expansion. No dose-limiting toxicities were observed, and expansion occurred at atezo 800 mg q2w and cobi 60 mg. Median follow-up for safety in CRC pts was 3.78 mo (range, 1.1-11.7). The most common treatment-related AEs included diarrhea (69.6%), fatigue (52.2%), dermatitis acneiform (43.5%), rash (34.8%), maculopapular rash (26.1%), pruritus (26.1%) and nausea (26.1%). Incidence of treatment-related G3-4 AEs was 34.8%. The only treatment-related G3-4 AE in ≥ 2 pts was diarrhea (8.7%). No G5 AEs were reported. The ORR was 17% (4 PR, 5 SD). Three responses were ongoing (range, 4.0 to 7.7 mo at time of data cutoff). Three responders were mismatch repair-proficient, and 1 was unknown. Response was not associated with baseline PD-L1 expression. Results from the serial biopsy cohort showed enhanced PD-L1 upregulation, CD8 T-cell infiltration and MHC I expression on treatment, providing mechanistic rationale for the combination. Conclusions: The combination of cobi and atezo in CRC is well tolerated at the maximum administered doses. These results show that pts with MSS CRC can respond to the combination of cobi and atezo, and provide support for continued evaluation of the combination. Clinical trial information: NCT01988896.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.3502

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 162

Metadata

Authors
Bendell, J. C., Kim, T. W., Goh, B. C., Wallin, J., Oh, D.-Y., Han, S.-W., Lee, C. B., Hellmann, M. D., Desai, J., Lewin, J. H., Solomon, B. J., Chow, L. Q. M., Miller, W. H., Gainor, J. F., Flaherty, K., Infante, J. R., Das-Thakur, M., Foster, P., Cha, E., & Bang, Y.-J.
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
3502-3502
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2890038459
Cited by
162
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.3502
The paper
Bendell, J. C., Kim, T. W., Goh, B. C., Wallin, J., Oh, D.-Y., Han, S.-W., Lee, C. B., Hellmann, M. D., Desai, J., Lewin, J. H., Solomon, B. J., Chow, L. Q. M., Miller, W. H., Gainor, J. F., Flaherty, K., Infante, J. R., Das-Thakur, M., Foster, P., Cha, E., & Bang, Y.-J. (2016). Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.3502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.